Pharmacology of azoles;Farmacología de los azoles

Revista Iberoamericana de Micologia

Volumn 24, Issue 3, 2007, Pages 223-227

  Azanza, José Ramón ^a   García Quetglas, Emilio ^a   Sádaba, Belén ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Fluconazole; Itraconazole; Pharmacology; Posaconazole; Voriconazole

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMPRENAVIR; ANTACID AGENT; ANTICOAGULANT AGENT; ARIPIPRAZOLE; ATORVASTATIN; BUDESONIDE; BUPIVACAINE; BUSPIRONE; CARBAMAZEPINE; CELECOXIB; CYCLOSPORIN A; CYTARABINE; CYTOCHROME P450; EFAVIRENZ; FLUCONAZOLE; GEMFIBROZIL; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; NEVIRAPINE; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; PYRROLE DERIVATIVE; RIFAMPICIN; SUCRALFATE; UNINDEXED DRUG; VORICONAZOLE;

ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; BLEEDING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; EDEMA; ENZYME INHIBITION; FOOD INTAKE; HEART ARRHYTHMIA; HUMAN; HYPOGLYCEMIA; HYPOTENSION; MYCOSIS; PHARMACODYNAMICS; PROTEIN BINDING; QT PROLONGATION; REVIEW; RHABDOMYOLYSIS; SEDATION; SIDE EFFECT; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT; UVEITIS;

EID: 35349020007     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-1406(07)70047-5     Document Type: Review

References (33)

1. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazol, voriconazole in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165-3169.
2. Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, Loebenberg D. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48: 137-142.
3. Azanza JR, Sádaba B, García Quetglas E, Mensa J. Guía práctica de interacciones de los antibióticos. Madrid, Icono Creación y Diseño, 2005.
4. Bafeltowska JJ, Buszman E. Pharmacokinetics of fluconazole in the cerebrospinal fluid of children with hydrocephalus. Chemotherapy 2005; 51: 370-376.
5. Ballesta S, Garcia I, Perea EJ, Pascual A. Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J Antimicrob Chemother 2005; 55: 785-787.
6. Capitano B, Potoski BA, Husain S, Zhang S, Paterson DL, Studer SM, McCurry KR, Venkataramanan R. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 2006; 50: 1878-1880.
7. Conte JE Jr, Golden JA, Kipps J, McIver M, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. Antimicrob Agents Chemother 2004; 48: 3823-3827.
8. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47: 2788-2795.
9. Courtney R, Sansone A, Smith W, Marbury T, Statkevich P, Martinho M, Laughlin M, Swan S. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005; 45: 185-192.
10. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57: 218-222.
11. Denes E, Pichon N, Debette-Gratien M, Bouteille B, Gaulier JM. Pharmacokinetics of voriconazole in the cerebrospinal fluid of an immunocompromised patient with a brain abscess due to Aspergillus fumigatus. Clin Infect Dis 2004; 39: 603-604.
12. Elter T, Sieniawski M, Gossmann A, Wickenhauser C, Schroder U, Seifert H, Kuchta J, Burhenne J, Riedel KD, Fätkenheuer G, Cornely OA. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents 2006; 28: 262-265.
13. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44: 211-220.
14. Gubbins PO, Krishna G, Sansone-Parsons A, Penzak SR, Dong L, Martinho M, Anaissie EJ. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006; 50: 1993-1999.
15. Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, Prince RA. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122: 42-47.
16. Hennig S, Wainwright CE, Bell SC, Miller H, Friberg LE, Charles BG. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 2006; 45: 1099-1114.
17. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48: 3543-3551.
18. Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther 2005; 30: 201-206.
19. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37: 728-732.
20. Mohr JF, Finkel KW, Rex JH, Rodriguez JR, Leitz GJ, Ostrosky-Zeichner L. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother 2004; 48: 3151-3153.
21. Mouton JW, Ven Peer A, de Beule K, Van Vliet A, Donnelly JP, Soons PA. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 2006; 50: 4096-4102.
22. Niwa T, Shiraga T, Takagi A. Drug-drug interaction of antifungal drugs. Yakugaku Zasshi 2005; 125: 795-805.
23. Peng LW, Lien YH. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. Am J Kidney Dis 2005; 45: 162-166.
24. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56 (Supl 1): i17-i22.
25. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56 (Supl 1): 10-16.
26. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 2003; 56 (Supl 1): 2-9.
27. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003; 56 (Supl 1): 17-23.
28. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730-1744.
29. Sadaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004; 36: 3226-3228.
30. Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA, Saltzman MA. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006; 50: 1881-1883.
31. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Töpelt K, Courtney R, Wexler D, Krishna G, Martinho M, Corcoran G, Raad I. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-666.
32. Von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006; 6: 6.
33. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-2172.